 |
DTIC ADA423723: A Phase I/II Trial of 13-Cis Retinoic Acid, Alpha I... |
 |
by Defense Technical Information Center |
 |
Thumbnail |
|
Download |
 |
Web page |
|
|
|
Advanced prostate cancer is only temporarily controlled |
|
with androgen ablation therapy. In order to overcome |
|
tumor resistance, we developed a epithelial cell line |
|
model to dissect out important mechanisms of resistance |
|
such as mutations in p53 and bcl-2 overexpression. In an |
|
attempt to sensitize these cells to paclitaxel (TAX), we |
|
found that 13-cis retinoic acid and alpha interferon |
|
(CRA/IFN) was capable of overcoming bcl-2 mediated |
|
resistance and reduced the expression of bcl-2 in human |
|
prostate cancer cells. We hypothesized that drugs, which |
|
could overcome bcl-2 mediated resistance, would improve |
|
chemotherapy response or duration of response in the |
|
clinic. We then translated these results to the clinic in |
|
a series of clinical trials. Recently, our phase II study |
|
with CRA/IFN/TAX was acceped as a National trial and is |
|
ongoing in the Eastern Cooperative Oncolo%y Group. Given |
|
recet studies demonstrating that the combination of |
|
estramustine and docetaxes (ET) has increased response |
|
against HRPC in the clinic, but limited median duration |
|
of response, and our studies of CRA/IFN in the laboratory |
|
and clinic, we hypothesized that CRA/IFN will improve the |
|
response rate, or duration of response, of ET in patients |
|
with HRPC. We will treat patients with HRPC with R.I.T. |
|
E. therapy in a phase I and II trial. |
|
|
|
Date Published: 2018-05-19 08:00:21 |
|
Identifier: DTIC_ADA423723 |
|
Item Size: 10269745 |
|
Language: english |
|
Media Type: texts |
|
|
|
# Topics |
|
DTIC Archive; DiPaola, Robert S ; UNI... |
|
|
|
# Collections |
|
dticarchive |
|
additional_collections |
|
|
|
# Uploaded by |
|
@chris85 |
|
|
|
# Similar Items |
|
View similar items |
|
|
|
PHAROS |
|
